Clinical Trial Update: Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

View source ↗

Summary

A clinical study is evaluating the effects of ravulizumab, a complement C5 inhibitor, on serum biomarkers sNfL and sGFAP in patients with Aquaporin-4–positive n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

Sponsor: National and Kapodistrian University of Athens | Conditions: NMOSD | Status: NOT_YET_RECRUITING